Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have received an average recommendation of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $13.86.

BCYC has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Finally, Needham & Company LLC cut their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 30th.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors have recently bought and sold shares of BCYC. Clearstead Advisors LLC grew its stake in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the last quarter. GAMMA Investing LLC raised its position in Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after purchasing an additional 6,447 shares during the last quarter. Portland Investment Counsel Inc. purchased a new stake in Bicycle Therapeutics in the 2nd quarter worth approximately $64,000. Royal Bank of Canada lifted its holdings in Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after buying an additional 3,788 shares during the period. Finally, R Squared Ltd purchased a new stake in Bicycle Therapeutics in the 1st quarter worth approximately $98,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Trading Down 5.1%

Shares of NASDAQ BCYC opened at $3.38 on Friday. The stock’s 50-day moving average is $3.96 and its 200 day moving average is $4.32. The stock has a market cap of $236.57 million, a price-to-earnings ratio of -1.24 and a beta of 1.68. Bicycle Therapeutics has a 1-year low of $3.33 and a 1-year high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. On average, analysts forecast that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines.

The company’s research and development activities are focused primarily on oncology.